The next-generation type 1.5 (αC-helix OUT) RAF inhibitor PLX8394 showed efficacy in treatment-naive BRAF-mutated NSCLC and in cases with acquired vemurafenib resistance, in both V600E and certain non-V600 models [100]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.